GlassScriptPhysician profile
Zandraetta L Tims-Cook
NPI 1538216338
$848,058.19
in general payments reported to CMS, 2019-2025
23 companies · $192K in 2025
The $192K reported for 2025 was more than what 99% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $91K · 2020: $54K · 2021: $66K · 2022: $84K · 2023: $174K · 2024: $187K · 2025: $192K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $360K · Travel and Lodging: $85K · Consulting Fee: $71K · Honoraria: $22K · Food and Beverage: $15K · Education: $65.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $360,210.50 |
| Travel and Lodging | $84,575.93 |
| Consulting Fee | $70,869.69 |
| Honoraria | $22,160.00 |
| Food and Beverage | $14,996.42 |
| Education | $65.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $799,349.06 | 2019-2025 | Dovato, Apretude, Cabenuva |
| Theratechnologies INC. | $25,422.93 | 2021-2025 | Egrifta, Egrifta Sv, Trogarzo |
| Glaxosmithkline, LLC. | $13,285.01 | 2019-2024 | |
| Gilead Sciences, INC. | $7,585.64 | 2019-2025 | Biktarvy |
| Janssen Biotech, INC. | $519.33 | 2019-2023 | Symtuza |
| Merck Sharp & Dohme LLC | $479.18 | 2020-2025 | Pifeltro, Delstrigo, Dificid |
| Janssen Products, LP | $317.58 | 2019-2021 | |
| Abbvie INC. | $176.85 | 2021-2025 | Teflaro, Dalvance |
| Janssen Scientific Affairs, LLC | $170.73 | 2021-2023 | Symtuza |
| La Jolla Pharmaceutical Company | $148.67 | 2021-2024 | Xerava |
| Lilly USA, LLC | $131.01 | 2023-2024 | Mounjaro |
| Insmed, INC. | $124.75 | 2022-2025 | Arikayce |
| Emd Serono, INC. | $68.77 | 2024-2025 | |
| Novo Nordisk INC | $67.78 | 2025 | Wegovy |
| Napo Pharmaceuticals INC | $40.67 | 2025 | Mytesi |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $31.21 | 2025 | Fetroja |
| Angiodynamics, INC. | $27.61 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $25.01 | 2024 | Opsumit, Uptravi |
| Tolmar, INC. | $20.82 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.53 | 2023 | Cuvitru |
| Esperion Therapeutics, INC. | $17.79 | 2020 | |
| Astellas Pharma US INC | $17.09 | 2024 | Veozah |
| Allergan, INC. | $12.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zandraetta Tims-Cook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.